---
title: "Anebulo Pharmaceuticals (ANEB) news: reverse split and delisting"
url: "https://aibio.space/companies/anebulo-pharmaceuticals/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ANEB reverse split and delisting news: Anebulo drops reverse split plan for $3.50-a-share self tender of up to 300,000 shares."
---

ANEB Anebulo Pharmaceuticals Inc OTC · United States

# Anebulo Pharmaceuticals (ANEB) news ANEB reverse split and delisting news

Listings · 2026-03-02

## [Anebulo Pharmaceuticals files Form 15 to end SEC reporting duties](https://aibio.space/news/anebulo-pharmaceuticals-files-form-15-end-sec-reporting-duties/)

Anebulo's March 2, 2026 Form 15 puts its SEC reporting duties to an end and gives 71 holders of record for its common stock, while the company's last reported cash figure was $9.0 million at December 31, 2025.

## Latest Anebulo Pharmaceuticals news

1. 2026-02-17 Listings [Anebulo Pharmaceuticals files Form 25 to withdraw its stock from Nasdaq](https://aibio.space/news/anebulo-pharmaceuticals-files-form-25-withdraw-stock-nasdaq/) Anebulo filed a Form 25 on February 17, 2026 to withdraw its common stock from Nasdaq as a voluntary withdrawal, while its lead drug candidate remains at an early stage and its cash fell in the second half of 2025.
2. 2026-02-06 Listings [Anebulo Pharmaceuticals to delist from Nasdaq and deregister with the SEC](https://aibio.space/news/anebulo-pharmaceuticals-delist-nasdaq-deregister-sec/) Anebulo's board approved leaving Nasdaq and ending SEC reporting, with a Form 25 due about February 17, 2026 and a Form 15 about February 27, while its lead drug candidate is still in early clinical work.
3. 2025-12-22 Listings [Anebulo drops reverse split plan for $3.50-a-share self tender of up to 300,000 shares](https://aibio.space/news/anebulo-drops-reverse-split-plan-3-50-share-self-tender-up-300-000/) Anebulo's board dropped a planned reverse split and will instead tender for up to 300,000 shares at $3.50, to keep its holder count below 300 for a go-private plan, while its lead drug rests on a Phase 2 study in healthy volunteers.

## Anebulo Pharmaceuticals at a glance

- **Ticker**: ANEB

- **Listing**: OTC

- **Country**: United States

- **Cash, Dec 31, 2025**: $9.0 million

### Related companies

- [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) NASDAQ: MIRM
- [Corvus Pharmaceuticals](https://aibio.space/companies/corvus-pharmaceuticals/) NASDAQ: CRVS
- [Vericel](https://aibio.space/companies/vericel/) NASDAQ: VCEL
- [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) NASDAQ: TKNO
- [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) NASDAQ: VKTX
- [Soligenix](https://aibio.space/companies/soligenix/) NASDAQ: SNGX
- [Coherus Oncology](https://aibio.space/companies/coherus-oncology/) NASDAQ: CHRS
- [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) NASDAQ: PCSA

### Also on OTC

- [Zivo Bioscience](https://aibio.space/companies/zivo-bioscience/) ZIVO
- [Nu-Med Plus](https://aibio.space/companies/nu-med-plus/) NUMD
- [NORTH BUD FARMS INC](https://aibio.space/companies/north-bud-farms/) NOBDF
- [HST Global](https://aibio.space/companies/hst-global/) HSTC
- [Jushi Holdings](https://aibio.space/companies/jushi/) JUSH
- [Elite Pharmaceuticals](https://aibio.space/companies/elite-pharmaceuticals/) ELTP

## What Anebulo Pharmaceuticals does

Anebulo Pharmaceuticals Inc is a clinical-stage pharmaceutical company developing treatments for cannabis-induced toxicity, including acute cannabis-induced toxicity in children and acute cannabinoid intoxication in adults. Its lead product candidate, selonabant (formerly ANEB-001), is a potent, small molecule antagonist of the CB1 receptor. It is orally bioavailable and has also been formulated for intravenous treatment. A Phase 2 study in the Netherlands reported complete results from Part A and Part B in a total of 134 subjects. Rather than proceeding directly to Phase 3 studies of oral selonabant in adults, the company is prioritizing an intravenous formulation for pediatric patients with unintentional cannabis poisoning. It held a Pre-IND meeting with the FDA in December 2024 and began a single ascending dose study of IV selonabant in healthy adults in the third quarter of calendar 2025. The company states that no approved medical treatments are currently available to specifically treat cannabis-induced toxicity. An observational study in patients presenting to emergency departments is ongoing.

| Product or program | What it is | Stage |
|---|---|---|
| Selonabant, oral | Oral CB1 receptor antagonist for acute cannabinoid intoxication in adults | Phase 2 completed; Phase 3 deferred |
| Selonabant, intravenous | IV formulation for pediatric unintentional cannabis poisoning | Single ascending dose study in healthy adults began in third quarter of calendar 2025 |

Summarised from the company's [10-K filed Sep 29, 2025](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016015/form10-k.htm).

## Anebulo Pharmaceuticals annual financials

| Line | FY ended Jun 30, 2025 | FY ended Jun 30, 2024 |
|---|---|---|
| Research and development | [$4.3 million](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016015/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016015/) |
| Net income (loss) | [-$8.5 million](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016015/) | [-$8.2 million](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016015/) |
| Cash from operations | [-$6.3 million](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016015/) | [-$8.1 million](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016015/) |
| Cash and equivalents | [$11.6 million](https://www.sec.gov/Archives/edgar/data/1815974/000149315226006446/) | [$3.1 million](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016015/) |

Latest balance sheet, Dec 31, 2025 (10-Q): cash and equivalents $9.0 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Anebulo Pharmaceuticals

Did Anebulo Pharmaceuticals do a reverse stock split?

Our latest story on this, dated Dec 22, 2025: "Anebulo drops reverse split plan for $3.50-a-share self tender of up to 300,000 shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/anebulo-drops-reverse-split-plan-3-50-share-self-tender-up-300-000/).

Was Anebulo Pharmaceuticals delisted?

Our latest story on this, dated Feb 17, 2026: "Anebulo Pharmaceuticals files Form 25 to withdraw its stock from Nasdaq". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/anebulo-pharmaceuticals-files-form-25-withdraw-stock-nasdaq/).

What is the ticker symbol of Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals Inc trades under the ticker ANEB on OTC.

Where is Anebulo Pharmaceuticals listed?

Anebulo Pharmaceuticals Inc is listed on OTC.

What is the SEC CIK of Anebulo Pharmaceuticals?

The SEC Central Index Key (CIK) for Anebulo Pharmaceuticals Inc is 1815974. Its filings are on SEC EDGAR.

How many shares does Anebulo Pharmaceuticals have outstanding?

40,784,731 shares as of 2026-02-06, per the cover page of its 10-Q filed 2026-02-12.

Which country or territory is Anebulo Pharmaceuticals listed under?

Our directory records Anebulo Pharmaceuticals Inc under United States.

What does Anebulo Pharmaceuticals do?

Our directory classifies Anebulo Pharmaceuticals Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Anebulo Pharmaceuticals?

The ISIN recorded for Anebulo Pharmaceuticals Inc is US0345691036.

Does aibio.space cover Anebulo Pharmaceuticals?

aibio.space lists Anebulo Pharmaceuticals Inc among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Anebulo Pharmaceuticals incorporated?

SEC records list its state or country of incorporation as DE.

What does Anebulo Pharmaceuticals develop?

Anebulo Pharmaceuticals Inc is a clinical-stage pharmaceutical company developing treatments for cannabis-induced toxicity, including acute cannabis-induced toxicity in children and acute cannabinoid intoxication in adults. Its lead product candidate, selonabant (formerly ANEB-001), is a potent, small molecule antagonist of the CB1 receptor.

What is Selonabant, oral from Anebulo Pharmaceuticals?

Selonabant, oral: Oral CB1 receptor antagonist for acute cannabinoid intoxication in adults Stage: Phase 2 completed; Phase 3 deferred.

What is Selonabant, intravenous from Anebulo Pharmaceuticals?

Selonabant, intravenous: IV formulation for pediatric unintentional cannabis poisoning Stage: Single ascending dose study in healthy adults began in third quarter of calendar 2025.

Is Anebulo Pharmaceuticals profitable?

Anebulo Pharmaceuticals Inc reported a net loss of $8.5 million for the fiscal year ended Jun 30, 2025, and used $6.3 million of cash in operations, per its annual report to the SEC.

## Investor discussion: Anebulo Pharmaceuticals

Members talk about Anebulo Pharmaceuticals (ANEB). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Anebulo Pharmaceuticals, newest first. Each line links the filing it comes from.

1. 2026-03-02 Listings Filed to end its SEC reporting. SEC Form 15-12G. [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315226008559/form15-12g.htm)
2. 2026-02-17 Listings Filed to remove its shares from exchange listing. SEC Form 25. [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315226007168/form25.htm)
3. 2026-02-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315226005463/ex99-1.htm)
4. 2026-01-27 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315226003718/ex99-1.htm)
5. 2025-12-22 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315225028676/ex99-1.htm)
6. 2025-12-22 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315225028680/formsc-toi.htm)
7. 2025-09-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315225013133/ex99-1.htm)
8. 2025-07-23 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315225011339/formpre14a.htm)
9. 2025-07-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315225011342/ex99-1.htm)
10. 2025-04-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1815974/000164117225004799/form8-k.htm)
11. 2025-03-03 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315225008861/form424b5.htm)
12. 2025-02-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315225008080/form8-k.htm)
13. 2024-12-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815974/000149315224051853/ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:ANEB on TradingView](https://www.tradingview.com/symbols/OTC-ANEB/).

## SEC filings and registration

- **SEC name**: Anebulo Pharmaceuticals, Inc.

- **CIK**: 1815974

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: ANEB (OTC)

- **State or country of incorporation**: DE

- **Fiscal year ends**: June 30

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY, TX, 78734

- **Phone**: 737 203 5270

- **Shares outstanding**: 40,784,731 as of 2026-02-06 (10-Q filed 2026-02-12)

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1815974/000149315226006446/form10-q.htm) filed 2026-02-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1815974/000149315226006428/form8-k.htm) filed 2026-02-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1815974/000149315226005463/form8-k.htm) filed 2026-02-06
- [8-K](https://www.sec.gov/Archives/edgar/data/1815974/000149315226004154/form8-k.htm) filed 2026-01-29
- [8-K](https://www.sec.gov/Archives/edgar/data/1815974/000149315226003718/form8-k.htm) filed 2026-01-27
- [8-K](https://www.sec.gov/Archives/edgar/data/1815974/000149315225028676/form8-k.htm) filed 2025-12-22
- [10-Q](https://www.sec.gov/Archives/edgar/data/1815974/000149315225022350/form10-q.htm) filed 2025-11-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/form8-k.htm) filed 2025-11-13

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001815974), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Anebulo Pharmaceuticals Inc is a public biotech or pharmaceutical company listed on OTC under the ticker ANEB, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Anebulo Pharmaceuticals Inc

- **Ticker**: ANEB

- **Listing**: OTC

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US0345691036

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-ANEB/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/anebulo-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Anebulo Pharmaceuticals (ANEB) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/anebulo-pharmaceuticals/